Azitra, Inc. AZTR
Azitra, Inc. was formed as a Delaware corporation on January 2, 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. We have not commenced commercial operations. Unless otherwise indicated, the terms "Azitra," Company," "we," "us," and "our" refer to Azitra, Inc. and its wholly-owned subsidiaries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $7.5K | $686.0K | $284.0K | — |
| R&D | $4.8M | $4.7M | $3.6M | $6.1M | — |
| SG&A | $6.1M | $6.3M | $4.5M | $3.6M | — |
| Total operating expenses | $11.0M | $11.0M | $8.1M | $9.7M | — |
| Operating income | -$11.0M | -$11.0M | -$7.5M | -$9.5M | — |
| Interest expense | $7.6K | $12.2K | $167.7K | $251.9K | — |
| Pre-tax income | -$10.9M | -$9.0M | -$11.3M | -$10.7M | — |
| Income tax | $8.3K | $9.0K | $17.3K | — | — |
| Net income | -$11.0M | -$9.0M | -$11.3M | -$10.7M | — |
| EPS, basic | -2.25 | -15.70 | -54.98 | -12.74 | — |
| EPS, diluted | -2.25 | -15.70 | -54.98 | -12.74 | — |
| Shares, diluted (wtd. avg.) | 4.9M | 571,162 | 229,866 | 1.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $2.1M | $4.6M | $1.8M | $3.5M | $8.0M |
| Receivables | $912 | $233 | — | $175.0K | — |
| Total current assets | $3.0M | $5.2M | $2.5M | $4.1M | — |
| Property, plant and equipment | $548.6K | $654.0K | $710.1K | $847.0K | — |
| Other intangibles | $316.7K | $246.4K | $210.9K | $219.6K | — |
| Total assets | $5.0M | $7.4M | $5.1M | $7.2M | — |
| Accounts payable | $399.4K | $490.3K | $897.3K | $784.7K | — |
| Total current liabilities | $1.1M | $1.4M | $1.6M | $2.2M | — |
| Total liabilities | $1.2M | $1.7M | $2.2M | $9.7M | — |
| Retained earnings | -$68.5M | -$57.6M | -$48.6M | -$37.3M | — |
| Total equity | $2.2M | $5.7M | $2.9M | -$36.3M | -$25.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$11.2M | -$10.2M | -$7.4M | -$8.3M | — |
| Depreciation and amortisation | $138.1K | $131.2K | $129.7K | $125.9K | — |
| Stock-based compensation | $62.7K | $245.1K | $151.5K | $184.5K | — |
| Capital expenditure | $24.2K | $8.6K | $26.5K | $33.1K | — |
| Investing cash flow | -$182.9K | -$379.2K | -$318.3K | -$336.8K | — |
| Financing cash flow | $8.9M | $13.3M | $6.0M | $4.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001701478-26-000013.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $284.0K | $686.0K | $7.5K | $0 |
| Gross profit | — | — | — | — | — |
| Net income | — | -$10.7M | -$11.3M | -$9.0M | -$11.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed Item 5.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |